Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis

• Conditions: Respiratory Infections; Community-Acquired Infections; Genetic Disorder; Host-Pathogen Interactions

• Registration Number: NCT03093220
• Lead Sponsor: Peking University People's Hospital

Brief Summary

Community-acquired pneumonia (CAP) is a heterogeneous disease causing great morbidity, mortality and health care burden globally. Typing methods for discriminating different clinical conditions of the same disease are essential to a better management of CAP. Traditional typing systems based separately on clinical manifestations (such as PSI and CURB-65), pathogens(bacterial types, virulence, drug resistance, etc) or host immune state (immunocompetent, immunocompromised or immunodeficiency). Thus, they are barely able to represent the real disease status nor to precisely predict the mortality.

As the development of multi-omic technologies, the relatedness of different phenotypes at a molecular level have revolutionized our ability to differentiate among patients. Our study is aimed at establishing a novel molecular typing method of CAP. Multi-omic (including genomics, transcriptomes, and metabolisms) data obtained from enrolled CAP patients and isolated pathogens would be integrated analyzed and interpreted. Tthe investigators believe that an appropriate molecular typing method would lead to revolutionary changes in current arrangements of CAP.

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-03
• Study Start: 2017-03
• Study First Submitted: 2017-03-15
• Study First Submitted QC: 2017-03-22
• Last Update Submitted: 2017-03-22
• Study First Posted: 2017-03-28
• Last Update Posted: 2017-03-28
• Primary Completion: 2018-03-31
• Study Completion: 2018-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• adult (aged > 16 years)
• diagnosed as community-acquired pneumonia

Exclusion Criteria

• being immunocompromised, including history of glucocorticoid taken for more than 1 month, history of immunosuppressive therapy, history of human immunodeficiency virus (HIV) infection, solid tumor or hematological malignancy
• history of long-term nursing home stays
• history of recently hospitalized (<90 days)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
30 day mortality	30 days after the onset of CAP	all-cause death in 30 days after the onset of CAP

Secondary Outcome Measures

Name	Time	Method
complications	30 days after the onset of CAP	nonfatal complications including critical organic or systematic dysfunction

Trial Locations

Locations (1)

Peking University People's Hospital; 🇨🇳 Beijing, Beijing, China